Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with chronic kidney disease: A systematic review and network meta-analysis

International Journal of Cardiology

Volumn 231, Issue , 2017, Pages 162-169

  Andò, Giuseppe ^a   Capranzano, Piera ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

Atrial fibrillation; Oral anticoagulation; Renal insufficiency

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; EDOXABAN; RIVAROXABAN; WARFARIN; VITAMIN K GROUP;

ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY FAILURE; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EMBOLISM; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; SYSTEMIC DISEASE; COMPLICATION; NETWORK META-ANALYSIS; ORAL DRUG ADMINISTRATION; THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; HUMANS; NETWORK META-ANALYSIS; RENAL INSUFFICIENCY, CHRONIC; THROMBOEMBOLISM; VITAMIN K;

EID: 85008477784     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.11.303     Document Type: Article

References (28)

1. [1] Soliman, E.Z., Prineas, R.J., Go, A.S., Xie, D., Lash, J.P., Rahman, M., et al. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am. Heart J. 159 (2010), 1102–1107.
2. [2] Go, A.S., Fang, M.C., Udaltsova, N., Chang, Y., Pomernacki, N.K., Borowsky, L., et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 119 (2009), 1363–1369.
3. [3] Piccini, J.P., Stevens, S.R., Chang, Y., Singer, D.E., Lokhnygina, Y., Go, A.S., et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation) and ATRIA (AnTicoagulation and risk factors in atrial fibrillation) study cohorts. Circulation 127 (2013), 224–232.
4. [4] Hart, R.G., Pearce, L.A., Asinger, R.W., Herzog, C.A., Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin. J. Am. Soc. Nephrol. 6 (2011), 2599–2604.
5. [5] Marinigh, R., Lane, D.A., Lip, G.Y., Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J. Am. Coll. Cardiol. 57 (2011), 1339–1348.
6. [6] Piccini, J.P., Hernandez, A.F., Zhao, X., Patel, M.R., Lewis, W.R., Peterson, E.D., et al. Quality of care for atrial fibrillation among patients hospitalized for heart failure. J. Am. Coll. Cardiol. 54 (2009), 1280–1289.
7. [7] Reinecke, H., Brand, E., Mesters, R., Schabitz, W.R., Fisher, M., Pavenstadt, H., et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J. Am. Soc. Nephrol. 20 (2009), 705–711.
8. [8] Capodanno, D., Capranzano, P., Giacchi, G., Calvi, V., Tamburino, C., Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: a meta-analysis of 50,578 patients. Int. J. Cardiol. 167 (2013), 1237–1241.
9. [9] Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Diener, H.C., Hacke, W., et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace: European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of. Cardiology 17 (2015), 1467–1507.
10. [10] Ruff, C.T., Giugliano, R.P., Braunwald, E., Hoffman, E.B., Deenadayalu, N., Ezekowitz, M.D., et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383 (2014), 955–962.
11. [11] Capranzano, P., Micciche, E., D'Urso, L., Privitera, F., Tamburino, C., Personalizing oral anticoagulant treatment in patients with atrial fibrillation. Expert. Rev. Cardiovasc. Ther. 11 (2013), 959–973.
12. [12] Ikeda, T., Use of oral anticoagulants according to the degree of renal impairment in Japanese patients with atrial fibrillation–which non-vitamin K antagonist oral anticoagulant to select?. Circ. J. 79 (2015), 1441–1443.
13. [13] Ando, G., Trio, O., Carerj, S., New oral anticoagulants versus vitamin K antagonists before cardioversion of atrial fibrillation: a meta-analysis of data from 4 randomized trials. Expert. Rev. Cardiovasc. Ther. 13 (2015), 577–583.
14. [14] Higgins, J., Green, S., Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, England. 2008, Wiley-Blackwell, Hoboken, NJ.
15. [15] Biondi-Zoccai, G., Abbate, A., Benedetto, U., Palmerini, T., D'Ascenzo, F., Frati, G., Network meta-analysis for evidence synthesis: what is it and why is it posed to dominate cardiovascular decision making?. Int. J. Cardiol. 182 (2015), 309–314.
16. [16] Dias, S., Sutton, A.J., Ades, A.E., Welton, N.J., Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med. Decis. Mak. 33 (2013), 607–617.
17. [17] Salanti, G., Ades, A.E., Ioannidis, J.P., Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J. Clin. Epidemiol. 64 (2011), 163–171.
18. [18] Jackson, D., White, I.R., Riley, R.D., Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Stat. Med. 31 (2012), 3805–3820.
19. [19] Bohula, E.A., Giugliano, R.P., Ruff, C.T., Kuder, J.F., Murphy, S.A., Antman, E.M., et al. Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial. Circulation 134 (2016), 24–36.
20. [20] Fox, K.A., Piccini, J.P., Wojdyla, D., Becker, R.C., Halperin, J.L., Nessel, C.C., et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur. Heart J. 32 (2011), 2387–2394.
21. [21] Hijazi, Z., Hohnloser, S.H., Oldgren, J., Andersson, U., Connolly, S.J., Eikelboom, J.W., et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (randomized evaluation of long-term anticoagulation therapy) trial analysis. Circulation 129 (2014), 961–970.
22. [22] Hohnloser, S.H., Hijazi, Z., Thomas, L., Alexander, J.H., Amerena, J., Hanna, M., et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur. Heart J. 33 (2012), 2821–2830.
23. [23] Hori, M., Matsumoto, M., Tanahashi, N., Momomura, S., Uchiyama, S., Goto, S., et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation - the J-ROCKET AF study. Circ. J. 76 (2012), 2104–2111.
24. [24] Nielsen, P.B., Lane, D.A., Rasmussen, L.H., Lip, G.Y., Larsen, T.B., Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. Clin. Res. Cardiol. 104 (2015), 418–429.
25. [25] Bonde, A.N., Lip, G.Y., Kamper, A.L., Hansen, P.R., Lamberts, M., Hommel, K., et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J. Am. Coll. Cardiol. 64 (2014), 2471–2482.
26. [26] Limdi, N.A., Beasley, T.M., Baird, M.F., Goldstein, J.A., McGwin, G., Arnett, D.K., et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. J. Am. Soc. Nephrol. 20 (2009), 912–921.
27. [27] Wheeler, D.S., Giugliano, R.P., Rangaswami, J., Anticoagulation-related nephropathy. J. Thromb. Haemost. 14 (2016), 461–467.
28. [28] Xu, Y., Holbrook, A.M., Simpson, C.S., Dowlatshahi, D., Johnson, A.P., Prescribing patterns of novel oral anticoagulants following regulatory approval for atrial fibrillation in Ontario, Canada: a population-based descriptive analysis. CMAJ Open 1 (2013), E115–E119.